IGM Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview

IGM Biosciences

02/05/2025 12:28

IGM Biosciences Inc IGMS.OQ IGMS.O is expected to show a rise in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

The Mountain View California-based  company is expected to report a 524.1% increase in revenue to $3.102 million from $497 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for IGM Biosciences Inc is for a loss of 41 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00​, above​ its last closing price of $1.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.72
-0.74
-0.61
Beat
17.3
Sep. 30 2024
-0.81
-0.80
-1.01
Missed
-26.2
Jun. 30 2024
-0.02
-0.04
-0.79
Missed
-1,991.1​
Mar. 31 2024
-0.83
-0.83
-0.83
Met
0.2
​​Dec. 31 2023
-0.96
-1.03
-1.01
Beat
2.2
Sep. 30 2023
-1.18
-1.21
-1.04
Beat
14.3​
Jun. 30 2023
-1.44
-1.43
-1.43
Met
0.3
Mar. 31 2023
-1.34
-1.36
-1.33
Beat
2.5

This summary was machine generated May 2 at 11:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)